Actinium Pharmaceuticals Inc.

ATNM | AMEX

Price Alert Chart Builder DCF Calculator

$1.22

+$0.02 (+1.67%)

Sep 22, 2026, 2:14 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.67%

(1D)

Rating

Updated: Aug 25, 2026

53.5

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $38.28M

1D Range

1.18 1.22

52W Range

0.74 1.74

Valuation (TTM)

PE 3.33

PB 1.24

EV/EBITDA 0.22

Valuation (NTM)

Forward PE N/A

Forward PEG -0.01

Price Target $11.07

Cash Flow

FCF Yield -61.8%

SBC Adj. FCF Yield -62.4%

SBC Impact -1.1%

Margins

Gross Margin 101.1%

Operating Margin 27.2%

FCF Margin -66.3%

Growth (CAGR)

Revenue 3Y | 5Y 820.4% | 108.6%

Dil EPS 3Y | 5Y 114.2% | 33.2%

FCF 3Y | 5Y 18.3% | -23.9%

Returns

ROA 28.2%

ROE 83.4%

ROIC 30.2%

Financial Health

Net Cash

$35.13M

Current Ratio 4.08

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other ...

Sector Healthcare

Industry Biotechnology

Employees 27

IPO Date Dec 26, 2012

Website www.actiniumpharma.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 13, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$4.95

Upside

+305.74%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞